CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors
Status: | Recruiting |
---|---|
Conditions: | Lung Cancer, Prostate Cancer, Skin Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Pancreatic Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/14/2019 |
Start Date: | February 15, 2018 |
End Date: | January 2022 |
Contact: | Vanessa Esquibel |
Email: | vesquibel@bioatla.com |
Phone: | 858-263-1598 |
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients With Advanced Solid Tumors
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors
This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety,
tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active
biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced
solid tumors.
This study will consist of a dose escalation phase and a dose expansion phase.
tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active
biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced
solid tumors.
This study will consist of a dose escalation phase and a dose expansion phase.
Inclusion Criteria:
- For the dose escalation phase: Patients with histologically or cytologically confirmed
locally advanced or metastatic solid tumor and have failed available standard of care
(SoC) therapy and for whom no curative therapy is available or who are not eligible,
intolerant to or refuse standard therapy.
- Patients must have measurable disease.
- For the dose expansion phase: Patients with locally advanced unresectable or
metastatic, non-small cell lung cancer (NSCLC), melanoma, and pancreatic ductal
adenocarcinoma (PDAC)
- Age ≥ 18 years.
- Adequate renal function
- Adequate liver function
- Adequate hematological function
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least three months.
Exclusion Criteria:
- Patients must not have clinically significant cardiac disease.
- Patients must not have known non-controlled CNS metastasis.
- Patients must not have received granulocyte colony stimulating factor (G-CSF) or
granulocyte/macrophage colony stimulating factor support 3 weeks prior to first BA3011
administration.
- Patients must not have had prior therapy with a conjugated or unconjugated auristatin
derivative/vinca-binding site targeting payload.
- Patients must not have Grade 2 or higher peripheral neuropathy.
- Patients must not have known human immunodeficiency virus (HIV) infection, active
hepatitis B and/or hepatitis C.
- Patients must not be women who are pregnant or breast feeding.
We found this trial at
8
sites
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Howard Burris, MD
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Matthew Taylor, MD
Phone: 503-418-9324
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Robert Doebele, MD
Phone: 720-848-9382
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: Eileen M. O'Reilly, MD
Phone: 646-888-4303
Click here to add this to my saved trials
Click here to add this to my saved trials